LIMERICK, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical devices for critical care and surgery, has been awarded a three-year innovative technology agreement with Novation for the ARROW® VPS® Vascular Positioning System®. This agreement includes the VPS console, stylets and pre-loaded stylets and is effective Sept. 1, 2012 through Aug. 31, 2015.
The ARROW VPS can replace the need for confirmatory chest X-ray in the presence of a stable Blue Bullseye by using state-of-the-art, real-time intravascular Doppler, ECG and advanced algorithmic logic to notify the clinician that the catheter tip has reached the optimal location. The preloaded option improves clinician ease of use for vascular navigation and catheter tip positioning.
The agreement was awarded through Novation’s innovative technology evaluation process. Novation’s Innovative Technology Program allows Novation to work with member councils and task forces to identify and review new or innovative technology that provides an incremental clinical benefit over existing products. The goal of Novation’s Innovative Technology Program is to work with hospital members to identify innovative technology that improves patient care or reduces the risk of harm to patients or providers, while simultaneously raising the standard of patient care and safety.
“We are pleased to partner with Novation in order to deliver innovative product lines to such a vital segment of the healthcare industry,” said Paul Molloy, President of the Vascular Division of Teleflex. “We are dedicated to providing technologies for clinicians who strive to make zero complications in vascular care a reality. This agreement demonstrates our continuous commitment to work together to reduce vascular access complications and improve ease of use for clinicians.”
Clinically, the ARROW VPS confirms accurate catheter tip position in the lower 1/3 of the SVC-Cavo-Atrial Junction, which has been proven to reduce complications such as thrombosis.1 The ARROW PICC features a TaperFree™ body designed to ensure consistent French size along the entire length of the catheter, which minimizes the risk of catheter-related thrombosis compared to reverse-taper catheters.2, 3 Additional information may be found at www.arrowintl.com.
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, Pa, Teleflex employs approximately 11,200 people worldwide and serves healthcare providers in more than 130 countries. Additional information about Teleflex can be obtained from the company's website at teleflex.com.
About Novation
Founded in 1998, Novation is the leading health care supply chain expertise and contracting company for the more than 65,000 members of VHA Inc. and UHC, two national health care alliances, Children’s Hospital Association, an alliance of the nation’s leading pediatric facilities, and Provista, LLC. Novation provides alliance members with sourcing services, as well as information and data services. Based in Irving, Tx, Novation develops and manages competitive contracts with more than 600 suppliers. VHA, UHC, and Provista members used Novation contracts to purchase more than $40 billion in 2011. Novation recently earned the coveted Ethics Inside® Certification from Ethisphere Institute, a leading international think tank dedicated to the research and promotion of best practices in corporate ethics and compliance. Novation was also named on Ethisphere’s World’s Most Ethical Companies list, and is the only company in the health care industry to earn both distinctions. To learn more about Novation, please visit www.novationco.com and follow @NovationNews.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Ethics Inside is a registered trademark of Ethisphere LLC.
Teleflex,
Arrow, TaperFree, Vascular Positioning System and VPS are trademarks or
registered trademarks of Teleflex Incorporated or its affiliates. ©2012
Teleflex Incorporated. All rights reserved. 2012-1282.
References:
1. Cadman, A., Lawrance, J., Fitzsimmons, L., Spencer-Shaw, A., &
Swindell, R. (2004). To clot or not to clot? That is the question in
central venous catheters. Clinical Radiology 59, 349–355.
2.
Trerotola, S, Stavropoulos, S, Mondschein, J, et al. Triple-lumen
peripherally inserted central catheter in patients in the critical care
unit: prospective evaluation. Radiology 2010;256(1):312-330.
3.
Nifong TP and McDevitt TJ. The effect of catheter to vein ratio on blood
flow rates in a simulated model of peripherally inserted central venous
catheters. Chest 2011;140;48-53.